Use of vancomycin pharmacokinetic–pharmacodynamic properties in the treatment of MRSA infections
- 10 January 2010
- journal article
- review article
- Published by Taylor & Francis Ltd in Expert Review of Anti-infective Therapy
- Vol. 8 (1), 95-106
- https://doi.org/10.1586/eri.09.123
Abstract
Vancomycin is a commonly used antimicrobial in patients with methicillin-resistant Staphylococcus aureus (MRSA) infections. Increasing vancomycin MIC values in MRSA clinical isolates makes the optimization of vancomycin dosing pivotal to its continued use. Unfortunately, limited data exist regarding the optimal pharmacokinetic–pharmacodynamic (PK–PD) goal to improve bacterial killing and clinical outcomes with vancomycin. The hallmark study in this area suggests that achieving an AUC to MIC ratio of over 400 improves the likelihood of achieving these outcomes. Challenges in the implementation of PK–PD-based dosing for vancomycin include current methodologies utilized in microbiology laboratories, as well as intra- and interpatient pharmacokinetic variability. Individualized dosing based on MIC and specific patient factors is important to achieve optimal outcomes from vancomycin therapy.Keywords
This publication has 65 references indexed in Scilit:
- Nine-Hospital Study Comparing Broth Microdilution and Etest Method Results for Vancomycin and Daptomycin against Methicillin-Resistant Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2009
- Vancomycin Ototoxicity: a Reevaluation in an Era of Increasing DosesAntimicrobial Agents and Chemotherapy, 2009
- Impact of Inoculum Size and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) on Vancomycin Activity and Emergence of VISA in an In Vitro Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2009
- Vancomycin MICs for Methicillin-Resistant Staphylococcus aureus Isolates Differ Based upon the Susceptibility Test Method UsedAntimicrobial Agents and Chemotherapy, 2008
- Relationship between Vancomycin MIC and Failure among Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia Treated with VancomycinAntimicrobial Agents and Chemotherapy, 2008
- Multicenter Evaluation of Vancomycin Dosing: Emphasis on ObesityAmerican Journal Of Medicine, 2008
- Larger Vancomycin Doses (at Least Four Grams per Day) Are Associated with an Increased Incidence of NephrotoxicityAntimicrobial Agents and Chemotherapy, 2008
- Evaluation of Accessory Gene Regulator ( agr ) Group and Function in the Proclivity towards Vancomycin Intermediate Resistance in Staphylococcus aureusAntimicrobial Agents and Chemotherapy, 2007
- Impaired Target Site Penetration of Vancomycin in Diabetic Patients following Cardiac SurgeryAntimicrobial Agents and Chemotherapy, 2006
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976